输注后PD-1+ CD8+ CAR T细胞可识别对CD19 CAR T细胞治疗有反应的非霍奇金淋巴瘤患者
本研究采用37色光谱流式细胞术对26例接受含CD28共刺激结构域商品化CAR T细胞治疗的非霍奇金淋巴瘤患者输注后样本进行高维单细胞分析,聚焦计算设门的CD8+ CAR T细胞。发现第14天时PD-1+ CD8+ CAR T细胞的存在与6个月内达到完全缓解高度相关,并识别出与反应和无进展生存相关的PD-1+ TCF1+干样及PD-1+ TIM3+效应样CAR T细胞亚型。
要点
- 第14天PD-1+ CD8+ CAR T细胞与6个月内完全缓解高度相关。
- PD-1+ TCF1+干样和PD-1+ TIM3+效应样CAR T细胞亚型与反应及无进展生存改善相关。
- PD-1+ CD8+ CAR+效应样T细胞亚群在完全缓解患者中增多,并与≥3级免疫效应细胞相关神经毒性综合征相关。
核心结论
- 输注后CD8+ CAR T细胞中PD-1阳性对达到完全缓解具有重要性,并识别出对含CD28 CAR T细胞反应的稳健生物标志物。
研究设计与样本
- 采用37色光谱流式细胞术对26例接受含CD28共刺激结构域商品化CAR T细胞治疗的非霍奇金淋巴瘤患者输注后样本进行高维单细胞分析,聚焦计算设门的CD8+ CAR T细胞。
主要发现
- 第14天时PD-1+ CD8+ CAR T细胞的存在与6个月内达到完全缓解高度相关。
- 识别出PD-1+ TCF1+干样CAR T细胞和PD-1+ TIM3+效应样CAR T细胞亚型,与反应和无进展生存等临床结局改善相关。
- 识别出具有效应样功能的PD-1+ CD8+ CAR+ T细胞亚群,在达到完全缓解的患者中增多,并与3级或以上免疫效应细胞相关神经毒性综合征相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Robust biomarkers and a complete understanding of CAR T-cell function in the postinfusion phase remain limited. Here, we used a 37-color spectral flow cytometry panel to perform high dimensional single-cell analysis of postinfusion samples in 26 patients treated with CD28 costimulatory domain containing commercial CAR T cells for NHL and focused on computationally gated CD8+ CAR T cells. We found that the presence of postinfusion Programmed cell death protein 1 (PD-1)+ CD8+ CAR T cells at the day 14 time point highly correlated with the ability to achieve complete response (CR) by 6 months. Further analysis identified multiple subtypes of CD8+ PD-1+ CAR T cells, including PD-1+ T cell factor 1 (TCF1)+ stem-like CAR T cells and PD-1+ T-cell immunoglobulin and mucin-domain containing-3 (TIM3)+ effector-like CAR T cells that correlated with improved clinical outcomes such as response and progression-free survival. Additionally, we identified a subset of PD-1+ CD8+ CAR+ T cells with effector-like function that was increased in patients who achieved a CR and was associated with grade 3 or higher immune effector cell-associated neurotoxicity syndrome. Here, we identified robust biomarkers of response to CD28 CAR T cells and highlight the importance of PD-1 positivity in CD8+ CAR T cells after infusion in achieving CR.
引用
- Denlinger N, Song NJ, Zhang X, et al. Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma. Blood Adv. 2024. PMID: 38607381. doi:10.1182/bloodadvances.2023012073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。